Del Sol Research Management LLC

1. Moderna TX, Inc. $3,514,519 211 payments
2. Braintree Laboratories, Inc. $1,974,790 128 payments
3. Allergan Inc. $747,252 125 payments
4. Exeltis, USA Inc. $317,718 89 payments
5. Sumitomo Pharma America, Inc. $207,175 123 payments
6. Genentech, Inc. $152,541 32 payments
7. Takeda Pharmaceuticals U.S.A., Inc. $146,492 39 payments
8. Adare Pharmaceuticals, Inc. $93,933 29 payments
9. Regeneron Pharmaceuticals, Inc. $80,979 29 payments
10. Boehringer Ingelheim International GmbH $77,480 52 payments

1. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $1,438,516 49 payments
2. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,112,414 64 payments
3. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $790,518 22 payments
4. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $698,494 16 payments
5. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $343,712 35 payments
6. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $309,643 29 payments
7. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $253,563 41 payments
8. A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age $250,319 16 payments
9. Bli4900-302 $229,024 16 payments
10. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $171,995 4 payments

1. Other $40,366 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.